LycoRed enters infant formula market
This article was originally published in The Tan Sheet
LycoRed announces Nov. 20 the launch of a line of "advanced oily blends featuring proprietary fatty acid premixes" designed for use in infant formula. The oily blend contains a "custom made composition of long chain polyunsaturated fatty acids and other oily soluble ingredients," the firm says. Product manufacturing will be at LycoRed's "new specialized lipid formulation facility" in the UK, the firm says. LycoRed Managing Director Peter Gallagher says, "Our goal is to penetrate this market with hot, new lipids that will allow manufacturers to create healthy and cutting-edge products. Investment in our premix facilities is the cornerstone of our strategy." LycoRed is the "leading European manufacturer for innovative premixes" and entered the U.S. premix market in July, according to a release...
You may also be interested in...
The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.
Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.